Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
about
Interventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for preventing oral mucositis for patients with cancer receiving treatmentPalifermin: role in the prevention of chemotherapy- and radiation-induced mucositisOral mucositis induced by anticancer treatments: physiopathology and treatments.Commentary: the pharmacological antioxidant amifostine -- implications of recent research for integrative cancer care.High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy.Autologous stem cell transplantation beyond 60 years of age.Clinacanthus nutans Extracts Are Antioxidant with Antiproliferative Effect on Cultured Human Cancer Cell LinesHigh-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCTMelphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection:A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.Keratinocyte growth factor.Evaluation of current and upcoming therapies in oral mucositis prevention.Systematic review of amifostine for the management of oral mucositis in cancer patients.Melphalan hydrochloride for the treatment of multiple myeloma.High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.Selenium supplementation in patients undergoing hematopoietic stem cell transplantation: effects on pro-inflammatory cytokines levels.Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients.Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.Trial of amifostine in autologous stem cell transplant.Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country.Lactobacillus brevis CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation.
P2860
Q24235217-2145CD8B-5052-4B0F-98F2-5EE35B5FDAB4Q24235482-DB7758E8-962C-4439-BA8F-39E11A075DC9Q24243046-B3C7D405-C729-4041-BD8C-574D380E7EFDQ28280759-6078FB65-53E4-4C3B-B183-60F87F1F7BCAQ35166803-D8105B85-1E7D-4EA0-A605-7AFC32D072F8Q36390553-9D7FAA36-5806-496F-B92B-30787AACB8B7Q36407446-82256E48-F85E-47C6-BAEB-038FCFCEFEDCQ36458432-620671DA-0EBD-4F51-90F7-6814350E5F32Q36623644-523D29D8-25A7-435F-9FAC-B72C379308BBQ36691989-330CD75E-5094-4C23-9A67-800E573288D1Q36902837-972D5157-C725-4A8A-9F5E-2041993210E0Q36973229-82E858F0-CEA2-49C2-9467-9F00476FE392Q37195567-67139D06-2E01-4858-98BA-ADF47E85D448Q37206924-35325E72-58F2-48DB-B7F2-CA970276F113Q37489900-B5709496-BEB0-4762-BA16-53A30F10C1C4Q37818225-B566BB05-AAFC-478A-8FB1-34063FB43511Q38050986-8185FAA1-879B-494C-ACDA-DD0B325AFE66Q38704146-4B9BABE9-2195-4991-AA80-CB6AF46C7F18Q41618393-A4FE12E1-21F7-49FE-A6E0-35723532869CQ42716642-B3B9CC7B-6068-4025-B5CB-9393F5AA6997Q43583135-DCD89C94-12FB-408B-A338-6320F65E2A63Q44254333-073B7D40-EC38-4125-8231-3881650D01F2Q46793139-F3D0458A-3F0C-4881-9230-9B83D16BC30BQ47181301-0344F301-060C-4E0E-A81E-1220C80DCDC8Q53206127-513D87EA-F14B-483B-BFA5-047BB9748AA4Q54918960-D08F6B0B-F335-46D5-82A1-5A30D55A5B61
P2860
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Prospective randomised trial o ...... ous stem cell transplantation.
@en
Prospective randomised trial o ...... ous stem cell transplantation.
@nl
type
label
Prospective randomised trial o ...... ous stem cell transplantation.
@en
Prospective randomised trial o ...... ous stem cell transplantation.
@nl
prefLabel
Prospective randomised trial o ...... ous stem cell transplantation.
@en
Prospective randomised trial o ...... ous stem cell transplantation.
@nl
P2093
P2860
P356
P1476
Prospective randomised trial o ...... ous stem cell transplantation.
@en
P2093
Australasian Leukemia and Lymphoma Group
H M Prince
J Bashford
J McKendrick
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704946
P407
P577
2005-05-01T00:00:00Z